All In Biotech

Drug Trial Radar · NCT00705679

Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women

Phase 2B Safety and Effectiveness Study of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate Tablet for the Prevention of HIV Infection in Women

Last checked: Nov 19, 2026Latest source record: Oct 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 5,029 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

5,029

Actual

Start

Aug 2009

Primary completion

Aug 2012

Study completion Aug 2012

Sponsor

Sponsor type
NIH
Collaborators
Microbicide Trials Network
First posted
Jun 26, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A new approach to HIV prevention currently being studied includes the use of microbicides, substances that kill microbes. Tenofovir disoproxil fumarate (TDF) and emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) are oral, FDA-approved, anti-HIV drugs, and tenofovir gel is an experimental microbicide. The purpose of this study is to determine the safety and effectiveness of daily tenofovir 1% gel compared to a vaginal placebo gel, and the safety and effectiveness of oral TDF and oral FTC/TDF compared to an oral placebo in preventing HIV infection among women at risk for sexually transmitted infections.

Conditions

  • HIV Infections

Interventions

  • Emtricitabine/tenofovir disoproxil fumarateDrug

    200 mg/300 mg tablet

  • Emtricitabine/tenofovir disoproxil fumarate placeboDrug

    placebo tablet

  • Tenofovir disoproxil fumarateDrug

    300 mg tablet

  • Tenofovir disoproxil fumarate placeboDrug

    placebo tablet

  • Tenofovir 1% vaginal gelDrug

    1 gm/100 ml of 1% gel

  • Tenofovir placeboDrug

    placebo gel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Person-years of Follow-up of Tenofovir 1% Gel and Vaginal Placebo Gel ArmsTime frame: For up to 30 months of follow-up
  2. Number of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel ArmsTime frame: For up to 30 months of follow-up
  3. Incidence Rate of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel ArmsTime frame: For up to 30 months of follow-up
  4. Person-years of Follow-up of Oral TDF and Oral Placebo ArmsTime frame: For up to 30 months of follow-up
  5. Number of HIV-1 Infections of Oral TDF and Oral Placebo ArmsTime frame: For up to 30 months of follow-up
  6. Incidence Rate of HIV-1 Infections of Oral TDF and Oral Placebo ArmsTime frame: For up to 30 months of follow-up
  7. Person-years of Follow-up of Oral TDF-FTC and Oral Placebo ArmsTime frame: For up to 30 months of follow-up
  8. Number of HIV-1 Infections of Oral TDF-FTC and Oral Placebo ArmsTime frame: For up to 30 months of follow-up
  9. Incidence Rate of HIV-1 Infections of Oral TDF-FTC and Oral Placebo ArmsTime frame: For up to 30 months of follow-up
  10. Extended Safety of Daily Tenofovir 1% Gel, Oral TDF, and Oral FTC/TDF in Women at Risk for Sexually Transmitted HIV Infection Based on Occurrence of Grade 2, 3, and 4 Adverse EventsTime frame: Throughout study, up to 2.5 years

Locations

15 sites in 3 countries. Site status is shown where the registry gives one.

  • CAPRISA Aurum CRS

    Klerksdorp, South Africa

  • Wits Reproductive Health and HIV Institute CRS (WRHI CRS)

    Johannesburg, Gauteng, South Africa

  • Soweto MTN CRS

    Johannesburg, Gauteng, South Africa

  • Overport CRS

    Asherville, KwaZulu-Natal, South Africa

  • Chatsworth CRS

    Chatsworth, KwaZulu-Natal, South Africa

  • eThekwini CRS

    Durban, KwaZulu-Natal, South Africa

  • Umkomaas CRS

    eMkhomazi, KwaZulu-Natal, South Africa

  • Tongaat CRS

    Tongaat, KwaZulu-Natal, South Africa

  • Verulam CRS

    Verulam, KwaZulu-Natal, South Africa

  • Botha's Hill CRS

    Westville, KwaZulu-Natal, South Africa

  • Isipingo CRS

    Westville, KwaZulu-Natal, South Africa

  • MU-JHU Research Collaboration CRS

    Kampala, Uganda

  • Seke South CRS

    Chitungwiza, Zimbabwe

  • Zengeza CRS

    Chitungwiza, Zimbabwe

  • Spilhaus CRS

    Harare, Zimbabwe

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.